Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Goldman

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2022
Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung CancerPhilippe Rochigneux, Aaron Lisberg, Alejandro Garcia, et al.
Oncotarget|February 11, 2016
Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technologyJames Che, Victor Yu, Manjima Dhar, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2014
A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumoursAnthony Tolcher, Jonathan Goldman, Amita Patnaik, et al.
Investigational New Drugs|October 12, 2012
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumorsMichael S Gordon, Lee S Rosen, David Mendelson, et al.
Scientific Reports|October 15, 2016
Label-free enumeration, collection and downstream cytological and cytogenetic analysis of circulating tumor cellsManjima Dhar, Edward Pao, Corinne Renier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2022
Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose ChemotherapyZev A Wainberg, Arun S Singh, Gottfried E Konecny, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2016
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping AlterationsAlexa B Schrock, Garrett M Frampton, James Suh, et al.
The New England Journal of Medicine|June 1, 2026
Selpercatinib in Early-Stage <i>RET</i> Fusion-Positive Non-Small-Cell Lung CancerYi-Long Wu, Maximilian Hochmair, Yi Yang, et al.
Future Oncology (London, England)|February 25, 2025
A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLCDavid Planchard, Pasi A Jänne, Ying Cheng, et al.
The New England Journal of Medicine|November 8, 2023
Osimertinib with or without Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLCDavid Planchard, Pasi A Jänne, Ying Cheng, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2022
Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung CancerPhilippe Rochigneux, Aaron Lisberg, Alejandro Garcia, et al.
Oncotarget|February 11, 2016
Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technologyJames Che, Victor Yu, Manjima Dhar, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2014
A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumoursAnthony Tolcher, Jonathan Goldman, Amita Patnaik, et al.
Investigational New Drugs|October 12, 2012
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumorsMichael S Gordon, Lee S Rosen, David Mendelson, et al.
Scientific Reports|October 15, 2016
Label-free enumeration, collection and downstream cytological and cytogenetic analysis of circulating tumor cellsManjima Dhar, Edward Pao, Corinne Renier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2022
Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose ChemotherapyZev A Wainberg, Arun S Singh, Gottfried E Konecny, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2016
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping AlterationsAlexa B Schrock, Garrett M Frampton, James Suh, et al.
The New England Journal of Medicine|June 1, 2026
Selpercatinib in Early-Stage <i>RET</i> Fusion-Positive Non-Small-Cell Lung CancerYi-Long Wu, Maximilian Hochmair, Yi Yang, et al.
Future Oncology (London, England)|February 25, 2025
A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLCDavid Planchard, Pasi A Jänne, Ying Cheng, et al.
The New England Journal of Medicine|November 8, 2023
Osimertinib with or without Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLCDavid Planchard, Pasi A Jänne, Ying Cheng, et al.
Pageof 4